share_log

Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target

Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target

Truist Securities重申對Immunovant的買入,維持48美元的目標股價
Moomoo 24/7 ·  03/25 12:11

Truist Securities analyst Robyn Karnauskas reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $48 price target.

Truist Securities分析師羅賓·卡瑙斯卡斯重申Immunovant(納斯達克股票代碼:IMVT)的買入並維持48美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論